Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) had its price target upped by Evercore ISI from $41.00 to $48.00 in a research report issued to clients and investors on Monday, FlyOnTheWall reports. Evercore ISI’s target price would indicate a potential upside of 200.56% from the company’s previous close. A number of other research firms also […]
Oppenheimer initiated coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) in a research note issued to investors on Wednesday, MarketBeat.com reports. The brokerage issued an outperform rating and a $40.00 price objective on the stock. A number of other research firms have also recently issued reports on CRNX. Robert W. Baird reduced their […]
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its price objective decreased by HC Wainwright from $35.00 to $33.00 in a research note issued to investors on Wednesday, MarketBeat reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Crinetics Pharmaceuticals’ Q3 2023 earnings at ($0.83) EPS, Q4 2023 […]